AstraZeneca Asthma Drug Fails COPD Study for a Second Time

AstraZeneca Plc’s Fasenra failed to meet its goal in a late-stage trial of patients with chronic obstructive pulmonary disease for a second time, a blow to the drugmaker’s efforts to expand the market for the asthma treatment.

The UK company will analyze the data from the trial to try to understand the results and share them with the scientific community, it said Wednesday.